Objective: To investigate the clinical efficacy of haploidentical high-dose in vitro non-T-cell-depleted peripheral blood hematopoietic stem cell transplantation (haplo-HDPSCT) in treating adult patients with Ph(+) acute lymphoblastic leukemia (Ph(+) ALL) . Method: This retrospective analysis was conducted on the clinical efficacy of 25 adult patients with Ph(+) ALL who underwent haplo-HDPSCT from July 2011 to June 2022 at our hospital. Results: This study included 25 patients with a median age of 27 (16-61) years, consisting of 12 males and 13 females. CR1 and ≥CR2 before transplantation were found in 23 and 2 cases, positive and negative minimal residual lesions were observed in 8 and 17 cases, and myeloablative conditioning and reduced-intensity conditioning were reported in 21 and 4 cases, respectively. Hematopoietic function was restored in all 25 patients after stem cell infusion. Of the 25 patients who underwent transplantation, 16 developed acute graft-versus-host disease (aGVHD). The cumulative incidence rates of Ⅱ-Ⅳ and Ⅲ-Ⅳ aGVHD were (40.4±11.3) % and (4.8±4.6) %, respectively. Four patients experienced relapse after transplantation, the cumulative relapse rates at 1 and 2 years after transplantation were (4.0±3.9) % and (14.5±7.9) %, respectively. The 2-year overall survival rate after transplantation was (81.3±8.5) % and the disease-free survival rate was (77.1±9.1) %. Conclusion: This study reveals that the unique haplo-HDPSCT protocol achieves good clinical efficacy in Ph(+) ALL treatment.
目的： 分析单倍体相合高剂量非体外去T细胞外周血造血干细胞移植（haplo-HDPSCT）治疗成人Ph(+)急性淋巴细胞白血病（Ph(+) ALL）的疗效。 方法： 回顾性分析2011年7月至2022年6月在新疆医科大学第一附属医院血液科接受haplo-HDPSCT模式25例成人Ph(+) ALL患者的临床疗效。 结果： 25例患者中，男12例，女13例，中位年龄27（16~61）岁。23例移植前处于第1次完全缓解（CR1）状态，2例处于第2次或以上完全缓解（≥CR2）状态，微小残留病（MRD）阳性、阴性分别为8、17例。清髓性预处理21例，减低剂量预处理4例。25例患者移植后均获得造血重建，16例发生急性移植物抗宿主病（GVHD），Ⅱ~Ⅳ、Ⅲ/Ⅳ度急性GVHD累积发生率分别为（40.4±11.3）%、（4.8±4.6）%；移植后1、2年累积复发率分别为（4.0±3.9）%、（14.5±7.9）%。移植后2年总生存、无病生存率分为（81.3±8.5）%、（77.1±9.1）%。 结论： haplo-HDPSCT治疗Ph(+) ALL具有较好的疗效。.
Keywords: Acute lymphoblastic leukemia; Haploidentical hematopoietic stem cell transplantation; MRD.